Helt enig LM, admin på nye HO er helt fraværende...

Published in Urology
Journal Scan / Research · January 24, 2019
Outcomes of Blue-Light Flexible Cystoscopy With Hexaminolevulinate in the Surveillance of Bladder Cancer

«TAKE-HOME MESSAGE

Blue-light cystoscopy has emerged as an effective tool to detect papillary tumors and carcinoma in situ during post-resection bladder cancer surveillance. The authors of this multi-institutional study evaluated 304 patients with a history of recurrent or high-grade bladder tumors, 262 of whom underwent blue-light enhanced flexible cystoscopy. Ultimately, 103 patients underwent surgical examination, of whom 63 were found to have malignancy. The authors reported that patients had a decreased anxiety level with blue-light cystoscopy, especially after negative pathology results. In all, 94% found it “worthwhile” and 94% would “do it again.” Additionally, 76% were willing to pay out-of-pocket for blue-light technology.

These data suggest that blue-light cystoscopy decreases patient anxiety and that most patients would be willing to pay out-of-pocket for this service. Should this technology become increasingly adopted into routine clinical practice, existing post–tumor resection guidelines may need to be studied and adjusted.
– Michael H. Johnson, MD»

Link:
https://www.practiceupdate.com/journalscan/53718/1/3?elsca1=emc_enews_expert-insight&elsca2=email&elsca3=practiceupdate_uro&elsca4=urology&elsca5=newsletter&rid=MzYxMjU0NzQ5NzkxS0&lid=10332481